Attacking hepatitis B virus cccDNA – The holy grail to hepatitis B cure

Journal of Hepatology

Volumn 64, Issue 1, 2016, Pages S41-S48

  Lucifora, Julie ^a,b   Protzer, Ulrike ^c,d  

^a CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d German Center of Infection Research   (Germany)

Author keywords

cccDNA; Hepatitis B virus; Liver

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; CIRCULAR DNA; COVALENTLY CLOSED CIRCULAR DNA; DNA CLEAVAGE ENZYME; ENZYME; GAMMA INTERFERON; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; INTERLEUKIN 6; LYMPHOTOXIN BETA RECEPTOR AGONIST; MITOGEN ACTIVATED PROTEIN KINASE; STAT3 PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VIRAL PROTEIN; VIRUS DNA;

ANTIVIRAL ACTIVITY; CELL NUCLEUS; CHRONIC HEPATITIS B; DNA STRUCTURE; EPIGENETICS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; MINICHROMOSOME; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; GENETICS; VIROLOGY; VIRUS REPLICATION;

DNA, CIRCULAR; DNA, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; VIRUS REPLICATION;

EID: 85010906014     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.02.009     Document Type: Review

References (71)

1. [1] Trepo, C., Chan, H.L., Lok, A., Hepatitis B virus infection. Lancet 384:9959 (2014), 2053–2063.
2. [2] Wursthorn, K., Lutgehetmann, M., Dandri, M., Volz, T., Buggisch, P., Zollner, B., et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 44 (2006), 675–684.
3. [3] Yan, H., Zhong, G., Xu, G., He, W., Jing, Z., Gao, Z., et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife, 1, 2012, e00049.
4. [4] Ni, Y., Lempp, F.A., Mehrle, S., Nkongolo, S., Kaufman, C., Falth, M., et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 146 (2014), 1070–1083.
5. [5] Guidotti, L.G., Rochford, R., Chung, J., Shapiro, M., Purcell, R., Chisari, F.V., Viral clearance without destruction of infected cells during acute HBV infection. Science 284 (1999), 825–829.
6. [6] Harrington, M., State of the (research) chimp. Lab Animal, 41, 2012, 31.
7. [7] Gheit, T., Sekkat, S., Cova, L., Chevallier, M., Petit, M.A., Hantz, O., et al. Experimental transfection of Macaca sylvanus with cloned human hepatitis B virus. J Gen Virol 83 (2002), 1645–1649.
8. [8] Lucifora, J., Vincent, I.E., Berthillon, P., Dupinay, T., Michelet, M., Protzer, U., et al. Hepatitis B virus replication in primary macaque hepatocytes: crossing the species barrier toward a new small primate model. Hepatology 51 (2010), 1954–1960.
9. [9] Dupinay, T., Gheit, T., Roques, P., Cova, L., Chevallier-Queyron, P., Tasahsu, S.I., et al. Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from Mauritius Island. Hepatology 58 (2013), 1610–1620.
10. [10] Yan, H., Peng, B., He, W., Zhong, G., Qi, Y., Ren, B., et al. Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide. J Virol 87 (2013), 7977–7991.
11. [11] Li, H., Zhuang, Q., Wang, Y., Zhang, T., Zhao, J., Zhang, Y., et al. HBV life cycle is restricted in mouse hepatocytes expressing human NTCP. Cell Mol Immunol 11 (2014), 175–183.
12. [12] Cui, X., Guo, J.T., Hu, J., Hepatitis B virus covalently closed circular DNA formation in immortalized mouse hepatocytes associated with nucleocapsid destabilization. J Virol 89 (2015), 9021–9028.
13. [13] Allweiss, L., Volz, T., Lutgehetmann, M., Giersch, K., Bornscheuer, T., Lohse, A.W., et al. Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration. J Hepatol 60 (2014), 500–507.
14. [14] Werle-Lapostolle, B., Bowden, S., Locarnini, S., Wursthorn, K., Petersen, J., Lau, G., et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126 (2004), 1750–1758.
15. [15] Mu, D., Yan, L., Tang, H., Liao, Y., A sensitive and accurate quantification method for the detection of hepatitis B virus covalently closed circular DNA by the application of a droplet digital polymerase chain reaction amplification system. Biotechnol Lett 37 (2015), 2063–2073.
16. [16] Margeridon, S., Carrouee-Durantel, S., Chemin, I., Barraud, L., Zoulim, F., Trepo, C., et al. Rolling circle amplification, a powerful tool for genetic and functional studies of complete hepatitis B virus genomes from low-level infections and for directly probing covalently closed circular DNA. Antimicrob Agents Chemother 52 (2008), 3068–3073.
17. [17] Zhong, Y., Han, J., Zou, Z., Liu, S., Tang, B., Ren, X., et al. Quantitation of HBV covalently closed circular DNA in micro formalin fixed paraffin-embedded liver tissue using rolling circle amplification in combination with real-time PCR. Clin Chim Acta 412 (2011), 1905–1911.
18. [18] Zhong, Y., Hu, S., Xu, C., Zhao, Y., Xu, D., Zhao, Y., et al. A novel method for detection of HBVcccDNA in hepatocytes using rolling circle amplification combined with in situ PCR. BMC Infect Dis, 14, 2014, 608.
19. [19] Pollicino, T., Belloni, L., Raffa, G., Pediconi, N., Squadrito, G., Raimondo, G., et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 130 (2006), 823–837.
20. [20] Kock, J., Rosler, C., Zhang, J.J., Blum, H.E., Nassal, M., Thoma, C., Generation of covalently closed circular DNA of hepatitis B viruses via intracellular recycling is regulated in a virus specific manner. PLoS Pathog, 6, 2010, e1001082.
21. [21] Li, H.C., Huang, E.Y., Su, P.Y., Wu, S.Y., Yang, C.C., Lin, Y.S., et al. Nuclear export and import of human hepatitis B virus capsid protein and particles. PLoS Pathog, 6, 2010, e1001162.
22. [22] Schmitz, A., Schwarz, A., Foss, M., Zhou, L., Rabe, B., Hoellenriegel, J., et al. Nucleoporin 153 arrests the nuclear import of hepatitis B virus capsids in the nuclear basket. PLoS Pathog, 6, 2010, e1000741.
23. [23] Nassal, M., HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut 64 (2015), 1972–1984.
24. [24] Guo, H., Jiang, D., Zhou, T., Cuconati, A., Block, T.M., Guo, J.T., Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation. J Virol 81 (2007), 12472–12484.
25. [25] Guo, H., Mao, R., Block, T.M., Guo, J.T., Production and function of the cytoplasmic deproteinized relaxed circular DNA of hepadnaviruses. J Virol 84 (2010), 387–396.
26. [26] Guo, H., Xu, C., Zhou, T., Block, T.M., Guo, J.T., Characterization of the host factors required for hepadnavirus covalently closed circular (ccc) DNA formation. PLoS One, 7, 2012, e43270.
27. [27] Koniger, C., Wingert, I., Marsmann, M., Rosler, C., Beck, J., Nassal, M., Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses. Proc Natl Acad Sci U S A 111 (2014), E4244–E4253.
28. [28] Cui, X., McAllister, R., Boregowda, R., Sohn, J.A., Ledesma, F.C., Caldecott, K.W., et al. Does tyrosyl DNA phosphodiesterase-2 play a role in hepatitis B virus genome repair?. PLoS One, 10, 2015, e0128401.
29. [29] Newbold, J.E., Xin, H., Tencza, M., Sherman, G., Dean, J., Bowden, S., et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol 69 (1995), 3350–3357.
30. [30] Bock, C.T., Schranz, P., Schroder, C.H., Zentgraf, H., Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell. Virus Genes 8 (1994), 215–229.
31. [31] Bock, C.T., Schwinn, S., Locarnini, S., Fyfe, J., Manns, M.P., Trautwein, C., et al. Structural organization of the hepatitis B virus minichromosome. J Mol Biol 307 (2001), 183–196.
32. [32] Belloni, L., Pollicino, T., De Nicola, F., Guerrieri, F., Raffa, G., Fanciulli, M., et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci U S A 106 (2009), 19975–19979.
33. [33] Benhenda, S., Ducroux, A., Riviere, L., Sobhian, B., Ward, M.D., Dion, S., et al. Methyltransferase PRMT1 is a binding partner of HBx and a negative regulator of hepatitis B virus transcription. J Virol 87 (2013), 4360–4371.
34. [34] Belloni, L., Allweiss, L., Guerrieri, F., Pediconi, N., Volz, T., Pollicino, T., et al. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 122 (2012), 529–537.
35. [35] Tropberger, P., Mercier, A., Robinson, M., Zhong, W., Ganem, D.E., Holdorf, M., Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation. Proc Natl Acad Sci U S A 112 (2015), E5715–E5724.
36. [36] Zoulim, F., Hepatitis B virus resistance to antiviral drugs: where are we going?. Liver Int 31 (2011), 111–116.
37. [37] Rehermann, B., Ferrari, C., Pasquinelli, C., Chisari, F.V., The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 2 (1996), 1104–1108.
38. [38] Cai, D., Mills, C., Yu, W., Yan, R., Aldrich, C.E., Saputelli, J.R., et al. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother 56 (2012), 4277–4288.
39. [39] Zhou, T., Guo, H., Guo, J.T., Cuconati, A., Mehta, A., Block, T.M., Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA surrogate in antiviral screening assays. Antiviral Res 72 (2006), 116–124.
40. [40] Lucifora, J., Arzberger, S., Durantel, D., Belloni, L., Strubin, M., Levrero, M., et al. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol 55 (2011), 996–1003.
41. [41] Lutgehetmann, M., Volz, T., Kopke, A., Broja, T., Tigges, E., Lohse, A.W., et al. In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice. Hepatology 52 (2010), 16–24.
42. [42] Guo, J.T., Pryce, M., Wang, X., Barrasa, M.I., Hu, J., Seeger, C., Conditional replication of duck hepatitis B virus in hepatoma cells. J Virol 77 (2003), 1885–1893.
43. [43] Reaiche-Miller, G.Y., Thorpe, M., Low, H.C., Qiao, Q., Scougall, C.A., Mason, W.S., et al. Duck hepatitis B virus covalently closed circular DNA appears to survive hepatocyte mitosis in the growing liver. Virology 446 (2013), 357–364.
44. [44] Summers, J., Jilbert, A.R., Yang, W., Aldrich, C.E., Saputelli, J., Litwin, S., et al. Hepatocyte turnover during resolution of a transient hepadnaviral infection. Proc Natl Acad Sci U S A 100 (2003), 11652–11659.
45. [45] Allweiss, L., Volz, T., Giersch, K., Lohse, A.W., Petersen, J., Lütgehetmann, M., et al. 127 Proliferation of hepatitis B virus infected human hepatocytes induces suppression of viral replication and rapid cccDNA decrease in humanized mice. J Hepatol 58 (2013), S56–S57.
46. [46] Quasdorff, M., Protzer, U., Control of hepatitis B virus at the level of transcription. J Viral Hepat 17 (2010), 527–536.
47. [47] Quasdorff, M., Hosel, M., Odenthal, M., Zedler, U., Bohne, F., Gripon, P., et al. A concerted action of HNF4alpha and HNF1alpha links hepatitis B virus replication to hepatocyte differentiation. Cell Microbiol 10 (2008), 1478–1490.
48. [48] Palumbo, G.A., Scisciani, C., Pediconi, N., Lupacchini, L., Alfalate, D., Guerrieri, F., et al. IL6 inhibits HBV transcription by targeting the epigenetic control of the nuclear cccDNA minichromosome. PLoS One, 10, 2015, e0142599.
49. [49] Riviere, L., Gerossier, L., Ducroux, A., Dion, S., Deng, Q., Michel, M.L., et al. HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase. J Hepatol 63 (2015), 1093–1102.
50. [50] van Breugel, P.C., Robert, E.I., Mueller, H., Decorsiere, A., Zoulim, F., Hantz, O., et al. Hepatitis B virus X protein stimulates gene expression selectively from extrachromosomal DNA templates. Hepatology 56 (2012), 2116–2124.
51. [51] Ducroux, A., Benhenda, S., Riviere, L., Semmes, O.J., Benkirane, M., Neuveut, C., The Tudor domain protein Spindlin1 is involved in intrinsic antiviral defense against incoming hepatitis B Virus and herpes simplex virus type 1. PLoS Pathog, 10, 2014, e1004343.
52. [52] Guo, Y.H., Li, Y.N., Zhao, J.R., Zhang, J., Yan, Z., HBc binds to the CpG islands of HBV cccDNA and promotes an epigenetic permissive state. Epigenetics 6 (2011), 720–726.
53. [53] Hosel, M., Quasdorff, M., Wiegmann, K., Webb, D., Zedler, U., Broxtermann, M., et al. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 50 (2009), 1773–1782.
54. [54] Protzer, U., Nassal, M., Chiang, P.W., Kirschfink, M., Schaller, H., Interferon gene transfer by a hepatitis B virus vector efficiently suppresses wild-type virus infection. Proc Natl Acad Sci U S A 96 (1999), 10818–10823.
55. [55] Belloni, L., Palumbo, G.A., Valente, S., Rotili, D., Pediconi, N., Mai, A., et al. Mimicking Interferon-α (IFNα) inhibitory activity on hepatitis B virus (HBV) transcription and replication by targeting the epigenetic control of nuclear cccDNA minichromosome with epigenetic small molecules. Hepatology, 56, 2012, 369A.
56. [56] Liu, F., Campagna, M., Qi, Y., Zhao, X., Guo, F., Xu, C., et al. Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog, 9, 2013, e1003613.
57. [57] Li, T., Robert, E.I., van Breugel, P.C., Strubin, M., Zheng, N., A promiscuous alpha-helical motif anchors viral hijackers and substrate receptors to the CUL4-DDB1 ubiquitin ligase machinery. Nat Struct Mol Biol 17 (2010), 105–111.
58. [58] Lucifora, J., Xia, Y., Reisinger, F., Zhang, K., Stadler, D., Cheng, X., et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343 (2014), 1221–1228.
59. [59] Xia, Y., Stadler, D., Lucifora, J., Reisinger, F., Webb, D., Hosel, M., et al. Interferon-gamma and tumor necrosis factor-alpha produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis. Gastroenterology 150 (2016), 194–205.
60. [60] Bohne, F., Chmielewski, M., Ebert, G., Wiegmann, K., Kurschner, T., Schulze, A., et al. T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes. Gastroenterology 134 (2008), 239–247.
61. [61] Krebs, K., Bottinger, N., Huang, L.R., Chmielewski, M., Arzberger, S., Gasteiger, G., et al. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelop proteins control virus replication in mice. Gastroenterology 145 (2013), 456–465.
62. [62] Belloni, L., Li, L., Palumbo, G.A., Chirapu, S.R., Calvo, L., Finn, M.G., et al. HAPs hepatitis B virus (HBV) capsid inhibitors block core protein interaction with the viral minichromosome and host cell genes and affect cccDNA transcription and stability. Hepatology, 54, 2013, 277A.
63. [63] Cradick, T.J., Keck, K., Bradshaw, S., Jamieson, A.C., McCaffrey, A.P., Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol Ther 18 (2010), 947–954.
64. [64] Schiffer, J.T., Swan, D.A., Stone, D., Jerome, K.R., Predictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approach. PLoS Comput Biol, 9, 2013, e1003131.
65. [65] Chen, J., Zhang, W., Lin, J., Wang, F., Wu, M., Chen, C., et al. An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases. Mol Ther 22 (2014), 303–311.
66. [66] Bloom, K., Ely, A., Mussolino, C., Cathomen, T., Arbuthnot, P., Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. Mol Ther 21 (2013), 1889–1897.
67. [67] Seeger, C., Sohn, J.A., Targeting hepatitis B virus with CRISPR/Cas9. Mol Ther Nucleic Acids, 3, 2014, e216.
68. [68] Kennedy, E.M., Bassit, L.C., Mueller, H., Kornepati, A.V., Bogerd, H.P., Nie, T., et al. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology 476 (2015), 196–205.
69. [69] Dong, C., Qu, L., Wang, H., Wei, L., Dong, Y., Xiong, S., Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. Antiviral Res 118 (2015), 110–117.
70. [70] Allweis, L., Dandri, M., Experimental in vitro and in vivo models for the study of human hepatitis B virus infection. J Hepatol 64 (2016), S17–S31.
71. [71] Durantel, D., Zoulim, F., New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. J Hepatol 64 (2016), S117–S131.